Sector Expert: Rajeev Jashnani

UBS Securities



Recent Quotes

"JNJ's canagliflozin and Xarelto could add $2.5B in revenues by 2016."

— Rajeev Jashnani, UBS Securities (2/21/13)
more >

"Prescription trends have ramped up for JNJ."

— Rajeev Jashnani, UBS Securities (12/17/12)
more >

"MDT's Resolute U.S. share has grown from 10% to 27%."

— Rajeev Jashnani, UBS Securities (9/20/12)
more >

"JNJ strongly prefers dividends over share repurchase."

— Rajeev Jashnani, UBS Securities (8/20/12)
more >

"We reiterate our Buy rating."

— Rajeev Jashnani, UBS Securities (7/12/12)
more >

"Trends for JNJ's Xarelto have ramped up appreciably."

— Rajeev Jashnani, UBS Securities (6/25/12)
more >



Due to permission requirements, not all quotes are shown.